Investments Iv, L.P.Pro Que... Net Worth

The estimated Net Worth of Investments Iv, L.P.Pro Que... is at least $25.6 Million dollars as of 27 November 2017. Investments Que owns over 209,298 units of UroGen Pharma Ltd stock worth over $17,152,448 and over the last 7 years Investments sold URGN stock worth over $8,497,499.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Investments Que URGN stock SEC Form 4 insiders trading

Investments has made over 1 trades of the UroGen Pharma Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently Investments sold 209,298 units of URGN stock worth $8,497,499 on 27 November 2017.

The largest trade Investments's ever made was selling 209,298 units of UroGen Pharma Ltd stock on 27 November 2017 worth over $8,497,499. On average, Investments trades about 209,298 units every 0 days since 2017. As of 27 November 2017 Investments still owns at least 1,242,031 units of UroGen Pharma Ltd stock.

You can see the complete history of Investments Que stock trades at the bottom of the page.

Insiders trading at UroGen Pharma Ltd

Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun, and Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.

What does UroGen Pharma Ltd do?

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.

Complete history of Investments Que stock trades at UroGen Pharma Ltd

UroGen Pharma Ltd executives and stock owners

UroGen Pharma Ltd executives and other stock owners filed with the SEC include:

• Elizabeth Barrett,
  President, Chief Executive Officer, Director
• Elizabeth A. Barrett,
  Pres, CEO & Director
• Mark Schoenberg,
  Chief Medical Officer
• Ron Bentsur,
  Advisor
• Dr. Mark P. Schoenberg,
  Chief Medical Officer
• Arie Belldegrun,
  Independent Chairman of the Board
• Jason Drew Smith,
  Gen. Counsel & Chief Compliance Officer
• Cynthia Butitta,
  Independent Director
• Kathryn Falberg,
  Independent Director
• Stuart Holden,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Fred Cohen,
  Independent Director
• Shawn Tomasello,
  Independent Director
• Molly Henderson CPA, MBA,
  Chief Financial Officer
• Elyse Seltzer,
  Chief Development Officer
• Polly Murphy,
  Chief Business Officer
• Jeff Bova,
  Chief Commercial Officer
• Jason Smith,
  Chief Compliance Officer, General Counsel
• Jim Ottinger,
  Executive Vice President, Regulatory Affairs and Quality
• Marina Konorty,
  Executive Vice President, Research & Development and Technical Operations
• Molly Henderson,
  Chief Financial Officer, Principal Accounting Officer
• James Ottinger R.ph.,
  Exec. VP of Regulatory Affairs & Quality
• Jeffrey Bova M.B.A.,
  Chief Commercial Officer
• Dr. Sari Prutchi-Sagiv Ph.D.,
  Marketing Director
• Eric Van Zanten,
  Sr. Director of Communications
• Jason Smith,
  Gen. Counsel & Chief Compliance Officer
• Sara Blum Sherman,
  Sr. Director of Investor Relations
• James A. Jr. Robinson,
  Director
• Investments Iv, L.P.Pro Que...,
  
• Stephen Mullennix,
  Chief Operating Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Leana Wen,
  Director
• Dong Kim,
  Chief Financial Officer
• Daniel George Wildman,
  Director